ES2162844T3 - Inhibicion de la disgenesia de ovarios, pubertad tardia o infantilismo sexual. - Google Patents

Inhibicion de la disgenesia de ovarios, pubertad tardia o infantilismo sexual.

Info

Publication number
ES2162844T3
ES2162844T3 ES94309469T ES94309469T ES2162844T3 ES 2162844 T3 ES2162844 T3 ES 2162844T3 ES 94309469 T ES94309469 T ES 94309469T ES 94309469 T ES94309469 T ES 94309469T ES 2162844 T3 ES2162844 T3 ES 2162844T3
Authority
ES
Spain
Prior art keywords
sexual
disgenesy
ovaries
childhood
late
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94309469T
Other languages
English (en)
Inventor
Jeffrey Alan Dodge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2162844T3 publication Critical patent/ES2162844T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Tea And Coffee (AREA)
  • Adjustment And Processing Of Grains (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Control Of Metal Rolling (AREA)
  • Tires In General (AREA)

Abstract

UN METODO PARA INHIBIR DISGENESIS DE OVARIOS, PUBERTAD RETARDADA, O INFANTILISMO SEXUAL, QUE COMPRENDE LA ADMINISTRACION A UN HUMANO QUE LO NECESITE, DE UNA CANTIDAD EFECTIVA DE UN COMPONENTE DE FORMULA (I), EN LA QUE R1 Y R3 SON INDEPENDIENTEMENTE HIDROGENO, -CH3, FORMULA (II) O (III), EN LAS QUE AR ES UN FENILO OPCIONALMENTE SUSTITUIDO; R2 ES ELEGIDO DEL GRUPO CONSISTENTE EN PIRROLIDINA, HEXAMETILENOAMINA, Y PIPERIDINA; O UNA SAL ACEPTABLE FARMACEUTICAMENTE DE UN SOLVENTE DE ELLAS.
ES94309469T 1993-12-21 1994-12-19 Inhibicion de la disgenesia de ovarios, pubertad tardia o infantilismo sexual. Expired - Lifetime ES2162844T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/170,946 US5451589A (en) 1993-12-21 1993-12-21 Methods of inhibiting ovarian dysgenesis, delayed puberty, or sexual infantilism

Publications (1)

Publication Number Publication Date
ES2162844T3 true ES2162844T3 (es) 2002-01-16

Family

ID=22621923

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94309469T Expired - Lifetime ES2162844T3 (es) 1993-12-21 1994-12-19 Inhibicion de la disgenesia de ovarios, pubertad tardia o infantilismo sexual.

Country Status (19)

Country Link
US (4) US5451589A (es)
EP (1) EP0662325B1 (es)
JP (1) JPH07215867A (es)
KR (1) KR950016733A (es)
CN (1) CN1107702A (es)
AT (1) ATE207748T1 (es)
AU (1) AU8153294A (es)
CA (1) CA2138500A1 (es)
CZ (1) CZ321694A3 (es)
DE (1) DE69428877T2 (es)
DK (1) DK0662325T3 (es)
ES (1) ES2162844T3 (es)
HU (1) HUT71228A (es)
IL (1) IL112049A0 (es)
NO (1) NO944917L (es)
PT (1) PT662325E (es)
RU (1) RU94045272A (es)
SI (1) SI0662325T1 (es)
ZA (1) ZA9410097B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69435137D1 (de) 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
ATE301129T1 (de) 1999-05-04 2005-08-15 Strakan Int Ltd Androgen glykoside und die androgenische aktivität davon
ES2228958T3 (es) * 2000-10-25 2005-04-16 Eli Lilly And Company Procedimiento de inhibicion de cataratas.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
AU8153294A (en) 1995-06-29
US5760060A (en) 1998-06-02
SI0662325T1 (en) 2002-06-30
HUT71228A (en) 1995-11-28
US5451589A (en) 1995-09-19
NO944917L (no) 1995-06-22
ZA9410097B (en) 1996-06-19
RU94045272A (ru) 1996-10-20
US5843962A (en) 1998-12-01
DE69428877T2 (de) 2002-04-25
IL112049A0 (en) 1995-03-15
PT662325E (pt) 2002-03-28
EP0662325A3 (en) 1995-10-11
EP0662325B1 (en) 2001-10-31
DE69428877D1 (de) 2001-12-06
DK0662325T3 (da) 2001-12-03
EP0662325A2 (en) 1995-07-12
ATE207748T1 (de) 2001-11-15
CA2138500A1 (en) 1995-06-22
JPH07215867A (ja) 1995-08-15
CZ321694A3 (en) 1995-08-16
NO944917D0 (no) 1994-12-19
KR950016733A (ko) 1995-07-20
CN1107702A (zh) 1995-09-06
US5719165A (en) 1998-02-17
HU9403654D0 (en) 1995-02-28

Similar Documents

Publication Publication Date Title
UA26930C2 (uk) Засіб для іhгібуваhhя еhдометріозу
ES2162844T3 (es) Inhibicion de la disgenesia de ovarios, pubertad tardia o infantilismo sexual.
DE69430465D1 (de) Hemmung uteriner Fibrose
DK0659416T3 (da) Inhibering af seborE og acne
NO944930D0 (no) Hemming av dysfunksjonell uterin blödning
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
ZA956988B (en) Methods of inhibiting primary endometrial hyperplasia.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 662325

Country of ref document: ES